Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)
Authors:
- K. KalinskyKKK. Kalinsky
- W.E. BarlowWBW.E. Barlow
- H.B. PathakHPH.B. Pathak
- R.V. PuriRPR.V. Puri
- A. MitraAMA. Mitra
- T. HomeTHT. Home
- J. GralowJGJ. Gralow
- K.S. AlbainKAK.S. Albain
- D.F. HayesDHD.F. Hayes
- S. DelalogeSDS. Delaloge
- N.U. LinNLN.U. Lin
- E.A. PerezEPE.A. Perez
- 24 July 2026
- journal article
- Published by Elsevier in Annals of Oncology
Abstract
No abstract availableFunding Information
- National Cancer Center (P20GM130423)
- National Institute of General Medical Sciences (P20GM130423)
- Breast Cancer Research Foundation (BCRF SPEC-2023)
- Breast Cancer Research Foundation (BCRF SPEC-2024)
- University of Kansas
- Hope Foundation
- National Cancer Institute (U10CA180888)
- National Cancer Institute (P30 CA168524)
- National Cancer Institute (U24CA196175)
- National Cancer Institute (U10CA180819)
- Children's Mercy Hospital
- National Institutes of Health
This publication has 31 references indexed in Scilit:
- Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trialsEuropean Journal of Cancer, 2021
- The role of anti-Müllerian hormone (AMH) in ovarian disease and infertilityJournal of Assisted Reproduction and Genetics, 2019
- The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancerEuropean Journal of Cancer, 2017
- A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancerEuropean Journal of Cancer, 2014
- Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patientsCancer, 2014
- Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerEuropean Journal of Cancer, 2013
- Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilizationFertility and Sterility, 2011
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Breast Cancer Research and Treatment, 2008
- Female reproductive ageing: current knowledge and future trendsTrends in Endocrinology & Metabolism, 2007
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996